Modality
Radioligand
MOA
FGFRi
Target
C5
Pathway
Notch
Ewing SarcomaPsoriasis
Development Pipeline
Preclinical
Dec 2018
→ Apr 2027
PreclinicalCurrent
NCT08816147
2,781 pts·Psoriasis
2018-12→2027-04·Terminated
2,781 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-241.1y awayInterim· Psoriasis
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Termina…
Catalysts
Interim
2027-04-24 · 1.1y away
Psoriasis
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08816147 | Preclinical | Psoriasis | Terminated | 2781 | PASI75 |
Competitors (10)